Want to see SE:VITR full AI Analyst Report?
Top Page
Vitrolife AB
(VITR)
Select Model
Select Model
Rating:51Neutral
Price Target:
kr97.00
▼(-27.07% Downside)
Action:Reiterated
Date:07/17/26
The score is held back primarily by deteriorated financial performance (sharp TTM revenue contraction and very large net losses), with weak technical momentum (negative MACD and price still below the 200-day average) adding further pressure. Offsetting factors include positive operating/free cash flow, conservative leverage, and a somewhat constructive earnings call focused on margin improvement, restructuring savings, and shareholder returns (buyback/dividend), but ongoing regional demand headwinds and cash conversion pressure limit upside.
Positive Factors
Recurring consumables franchise
Vitrolife's consumables are recurring, procedure-tied products. Record SEK 358m consumables and 15% organic Americas growth indicate durable, repeatable revenue less tied to capital cycles. That supports predictable topline and recurring cash flow over multiple quarters as clinics continue procedures.
Negative Factors
Sharp revenue decline and deep losses
A ~41% TTM revenue contraction and very large net losses materially erode equity and produce deeply negative ROE. Persistent top-line decline and loss-making results impair reinvestment capacity, could constrain strategic initiatives, and threaten long-term financial flexibility if recovery stalls.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables franchise
Vitrolife's consumables are recurring, procedure-tied products. Record SEK 358m consumables and 15% organic Americas growth indicate durable, repeatable revenue less tied to capital cycles. That supports predictable topline and recurring cash flow over multiple quarters as clinics continue procedures.
Read all positive factors
Vitrolife AB (VITR) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr12.32B
Dividend Yield1.24%
Average Volume (3M)92.36K
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue Growth-4.21%
EPS Growth-1194.93%
CountrySE
Employees1,103
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-36.80
Shares Outstanding135,447,190
10 Day Avg. Volume105,869
30 Day Avg. Volume92,365
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.35
Price to Sales (P/S)5.39
P/FCF Ratio40.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.11
Revenue Forecast (FY)kr3.45B
Vitrolife AB Business Overview & Revenue Model
Company Description
Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, su...
How the Company Makes Money
Vitrolife makes money primarily by selling products and services to fertility clinics, IVF laboratories, and related healthcare providers involved in assisted reproduction. Its core revenue streams include: (1) Consumables and media: recurring sal...
Vitrolife AB Earnings Call Summary
Earnings Call Date:Jul 16, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 22, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: strong execution on profitability, margin expansion, cost reductions, product launches and capital allocation (share buyback), but meaningful top-line headwinds from region-specific disruptions (Middle East), structural demand weakness in China, declines and strategic exits in Genetics, and some cash‑flow pressure. Management is emphasizing profitable, disciplined growth rather than aggressive top-line expansion in the near term.Positive Updates
Record Consumables Revenue and Strong Americas Media Growth
Recorded Consumables revenue of SEK 358 million in the quarter with 15% organic growth in the Americas; significant media wins in North and South America driving consumables expansion.
Negative Updates
Revenue Softness and Modest Organic Growth
Net sales of SEK 857 million, a -2% decline in SEK YoY. The top-line split: organic growth +1%, exit of NACE/GPDx accounted for -2%, and negative currency effects ~-1%.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Consumables Revenue and Strong Americas Media Growth
Recorded Consumables revenue of SEK 358 million in the quarter with 15% organic growth in the Americas; significant media wins in North and South America driving consumables expansion.
Read all positive updates
Company Guidance
The call reiterated a focus on profitable growth (no new formal top‑line guidance), operational excellence and continued restructuring to deliver SEK 65m of annual run‑rate savings (SEK 55m reserve, about half consumed so far, completion expected end‑Q3); the board approved a share repurchase program up to SEK 500m (through AGM 2027) and reconfirmed dividend policy (FY2025 dividend SEK 1.10/share, SEK 149m). Management noted the >10% organic target set in 2023 remains contingent on underlying market growth of ~5–7% and market recovery (no immediate change to that target), while quarter metrics underpinning the guidance were: net sales SEK 857m (‑2% in SEK, +1% organic, exits NACE/GPDx ‑2%, FX ‑1%), gross income SEK 517m (gross margin 60.3%, ~+2pp y/y), EBITDA SEK 295m (34.4% margin vs 27.8% prior), net income SEK 129m, EPS SEK 0.95, net debt/EBITDA 0.7x, and continued regional/product datapoints (Consumables record SEK 358m and +15% organic in Americas; EMEA 37% of revenue; Americas 34%; APAC 29%).Vitrolife AB Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
66
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.39B | 3.44B | 3.61B | 3.51B | 3.23B | 1.68B |
| Gross Profit | 1.82B | 1.75B | 2.13B | 1.98B | 1.79B | 1.05B |
| EBITDA | -4.43B | -4.41B | 1.23B | -3.19B | 977.00M | 579.60M |
| Net Income | -4.98B | -5.01B | 513.00M | -3.85B | 394.00M | 341.00M |
Balance Sheet | ||||||
| Total Assets | 11.30B | 11.12B | 17.45B | 16.33B | 20.55B | 19.43B |
| Cash, Cash Equivalents and Short-Term Investments | 823.00M | 809.00M | 1.14B | 861.00M | 578.00M | 630.09M |
| Total Debt | 1.60B | 1.60B | 2.09B | 2.09B | 2.23B | 2.48B |
| Total Liabilities | 3.17B | 3.23B | 3.81B | 3.61B | 3.81B | 4.09B |
| Stockholders Equity | 8.13B | 7.89B | 13.64B | 12.72B | 16.74B | 15.32B |
Cash Flow | ||||||
| Free Cash Flow | 613.00M | 460.00M | 815.00M | 638.00M | 549.00M | 321.86M |
| Operating Cash Flow | 727.00M | 635.00M | 907.00M | 757.00M | 636.00M | 384.31M |
| Investing Cash Flow | -236.00M | -302.00M | -377.00M | -124.00M | -144.00M | -6.52B |
| Financing Cash Flow | -583.00M | -553.00M | -286.00M | -300.00M | -582.00M | 5.75B |
Vitrolife AB Technical Analysis
Negative
133.00
Price Trends
89.84
Negative
95.92
Negative
107.80
Negative
Market Momentum
0.08
Negative
47.24
Neutral
47.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VITR, the sentiment is Negative. The current price of 133 is above the 20-day moving average (MA) of 88.26, above the 50-day MA of 89.84, and above the 200-day MA of 107.80, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 47.24 is Neutral, neither overbought nor oversold. The STOCH value of 47.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VITR.
Vitrolife AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr3.64B | 27.99 | 14.59% | 1.96% | -1.64% | -14.61% | |
75 Outperform | kr65.40B | 24.38 | 8.88% | 2.06% | -3.56% | 79.60% | |
71 Outperform | kr9.30B | 100.36 | 4.13% | ― | 8.79% | -20.48% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | kr544.93M | -64.58 | -2.84% | ― | -13.72% | 52.47% | |
51 Neutral | kr12.32B | -2.40 | -53.29% | 0.80% | -4.21% | -1194.93% | |
51 Neutral | kr1.15B | -1.17 | -51.81% | ― | -24.97% | -366.73% |
* General Sector Average
SE:VITR
Vitrolife AB
89.60
-46.10
-33.97%
SE:GETI.B
Getinge
240.60
39.34
19.55%
SE:BICO
BICO Group AB Class B
16.68
-10.32
-38.22%
SE:CEVI
CellaVision AB
154.80
-5.24
-3.27%
SE:XVIVO
Xvivo Perfusion AB
281.60
98.00
53.38%
SE:BACTI.B
Bactiguard Holding AB
15.20
-12.80
-45.71%
Vitrolife AB Corporate Events
Vitrolife lifts margins and launches SEK 500m buyback despite flat sales
Jul 16, 2026
Vitrolife AB reported second-quarter sales of SEK 857 million, down slightly year-on-year, with a 1% decline in local currencies but 1% organic growth when excluding exited NACE and GDPX lines. Regional sales were flat to marginally positive in EM...
Vitrolife launches SEK 500 million share buyback alongside dividend
Jul 15, 2026
Vitrolife Group’s board has approved a share repurchase programme of up to SEK 500 million to run from 17 July 2026 until the next Annual General Meeting, aiming to optimise the capital structure and enhance shareholder value. The buyback, c...
Vitrolife schedules Q2 2026 report release and investor presentation
Jul 1, 2026
Vitrolife Group, a Gothenburg-based medical device and genetic testing company specializing in reproductive health, serves over 125 countries through a mix of direct operations and distributors, and is listed on Nasdaq Stockholm. The company emplo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.